PMID- 28978039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 40
DP  - 2017 Sep 15
TI  - Antitumor immunity induced by VE-cadherin modified DC vaccine.
PG  - 67369-67379
LID - 10.18632/oncotarget.18654 [doi]
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells. A strong 
      interest has been developed in DC vaccines for cancer immunotherapy. Besides, 
      angiogenesis is essential for tumor growth. VE-cadherin has a crucial function in 
      various aspects of vascular biological functions. Here, we produced the full 
      VE-cadherin gene modified DC vaccine (DC-VEC). Its antitumor immunity and chief 
      mechanism driving antitumor effect was evaluated. Analyses were performed 
      including test of antitumor antibody, CTL-mediated cytotoxicity experiment, 
      vascular density, evaluation of the variation of cells and cytokines in 
      immunoregulation. Its damage to the major organs was also evaluated. DC-VEC 
      vaccine resulted in retarded tumor progression and prolonged survival in mice. In 
      DC-VEC group, large amount of immunoglobulin was generated, T cells exhibited 
      greater cytotoxicity against VE-cadherin, and tumor angiogenesis was suppressed. 
      Besides, a decrease of VEGF-A and TGF-beta1, and an increase of IL-4 and IFN-gamma were 
      observed. CD4(+) and CD8(+) T cells were higher, with increased IFN-gamma secretion. 
      The percentage of myeloid-derived suppressor cells and regulatory T cells 
      decreased mildly. Also, it had no pathologic changes in major organs. DC-VEC 
      vaccine represents a promising antitumor immunotherapy. The main mechanism is 
      associated with its anti-angiogenesis and immunoregulation response.
FAU - Zhou, Jing
AU  - Zhou J
AD  - The Department of Medical Oncology, Cancer Center, State Key Laboratory of 
      Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, 
      Sichuan University, Sichuan, China.
FAU - Xi, Yufeng
AU  - Xi Y
AD  - State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation 
      Center for Biotherapy, West China Hospital, Sichuan University, Sichuan, China.
FAU - Mu, Xiyan
AU  - Mu X
AD  - Department of Gynecology and Obstetrics, Key Laboratory of Obstetrics and 
      Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, 
      West China Second Hospital, Sichuan University, Sichuan, China.
FAU - Zhao, Rongce
AU  - Zhao R
AD  - Division of Liver Transplantation, Department of Liver Surgery, West China 
      Hospital, Sichuan University, Sichuan, China.
FAU - Chen, Hongdou
AU  - Chen H
AD  - The Department of Medical Oncology, Cancer Center, State Key Laboratory of 
      Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, 
      Sichuan University, Sichuan, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - The Department of Medical Oncology, Cancer Center, State Key Laboratory of 
      Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, 
      Sichuan University, Sichuan, China.
FAU - Wu, Yang
AU  - Wu Y
AD  - State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation 
      Center for Biotherapy, West China Hospital, Sichuan University, Sichuan, China.
FAU - Li, Qiu
AU  - Li Q
AD  - The Department of Medical Oncology, Cancer Center, State Key Laboratory of 
      Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, 
      Sichuan University, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20170627
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5620179
OTO - NOTNLM
OT  - DC
OT  - VE-cadherin
OT  - anti-angiogenesis
OT  - immunoregulation
OT  - vaccine
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2017/10/06 06:00
MHDA- 2017/10/06 06:01
PMCR- 2017/09/15
CRDT- 2017/10/06 06:00
PHST- 2017/03/10 00:00 [received]
PHST- 2017/05/23 00:00 [accepted]
PHST- 2017/10/06 06:00 [entrez]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2017/10/06 06:01 [medline]
PHST- 2017/09/15 00:00 [pmc-release]
AID - 18654 [pii]
AID - 10.18632/oncotarget.18654 [doi]
PST - epublish
SO  - Oncotarget. 2017 Jun 27;8(40):67369-67379. doi: 10.18632/oncotarget.18654. 
      eCollection 2017 Sep 15.